Australia - Inggris - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; microcrystalline cellulose - fast temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe freely.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: crospovidone; pregelatinised maize starch; povidone; purified water; microcrystalline cellulose; magnesium stearate; stearic acid - temporary relief of the following cold and flu symptoms: nasal congestion, sinus pain, runny nose, headache and body aches & pains. reduces fever

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium nitrite - solution for injection - 30 milligram(s)/millilitre - sodium nitrite

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium nitrite - solution for injection - 30 milligram(s)/millilitre - sodium nitrite

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium thiosulfate - solution for injection - 250 milligram(s)/millilitre - antidotes; thiosulfate

Israel - Inggris - Ministry of Health

medison pharma ltd - fentanyl as citrate - nasal spray, solution - fentanyl as citrate 1 mg / 1 ml - fentanyl - pecfent is indicated for the management of breakthrough pain (btp) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Israel - Inggris - Ministry of Health

medison pharma ltd - fentanyl as citrate - nasal spray, solution - fentanyl as citrate 4 mg / 1 ml - fentanyl - pecfent is indicated for the management of breakthrough pain (btp) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bisacodyl 5mg - enteric coated tablet - 5 mg - active: bisacodyl 5mg excipient: calcium carbonate colloidal silicon dioxide gelatin lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone   purified talc   quinoline yellow silicon sodium starch glycolate starch sucrose